U.S. biotech firm partners with Japanese company for cancer drug

12/16/2008 | American City Business Journals

Yakult Honsha signed a licensing pact that allows it to market Celsion's ThermoDox, an experimental cancer treatment, in Japan. Celsion, a biotech firm in Columbia, Md., will receive $2.5 million upfront and is entitled to $18 million more once the drug gets clearance from Japanese regulators. Yakult will conduct clinical studies of ThermoDox in Japan.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA